Bellevue Group’s Adaptive Biotechnologies ADPT Stock Holding History

Bellevue Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.92M	Buy	89,439 +13,258	+17%	+$203K	0.04%	95
2026 Q1	$1.06M	Sell	76,181 -221,909	-74%	-$3.54M	0.03%	90
2025 Q4	$4.84M	Buy	298,090 +129,614	+77%	+$2.12M	0.09%	77
2025 Q3	$2.52M	Buy	+168,476	New	+$2.05M	0.05%	93
2023 Q1	–	Sell	-2,960,131	Closed	-$22.6M	–	162
2022 Q4	$22.6M	Sell	2,960,131 -319,489	-10%	-$2.49M	0.3%	78
2022 Q3	$23.4M	Sell	3,279,620 -259,435	-7%	-$2.44M	0.34%	77
2022 Q2	$28.6M	Buy	3,539,055 +393,762	+13%	+$3.46M	0.4%	67
2022 Q1	$43.7M	Buy	3,145,293 +1,176,862	+60%	+$18.5M	0.51%	62
2021 Q4	$55.2M	Buy	1,968,431 +632,408	+47%	+$19.4M	0.57%	59
2021 Q3	$45.4M	Buy	1,336,023 +373,671	+39%	+$13.5M	0.46%	68
2021 Q2	$39.3M	Buy	+962,352	New	+$37.4M	0.38%	80

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group's ADPT Position: Q2 2026 in Review

Bellevue Group increased its Adaptive Biotechnologies (ADPT) stake by 17% in Q2 2026, buying an estimated $203K and bringing the position to 89,439 shares worth $1.92M. The position accounts for 0.04% of the portfolio, ranked #95.

Bellevue Group first reported a position in ADPT in Q2 2021 and has held it in 11 quarters since. The position peaked at $55.2M in Q4 2021. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Bellevue Group held 89,439 shares of Adaptive Biotechnologies worth $1.92M as of Q2 2026.
Bellevue Group bought 13,258 Adaptive Biotechnologies shares in Q2 2026, an estimated $203K.
Adaptive Biotechnologies made up 0.04% of Bellevue Group's portfolio in Q2 2026, its #95 holding.
Bellevue Group first reported a position in Adaptive Biotechnologies in Q2 2021 and has held it in 11 quarters since.
Bellevue Group's Adaptive Biotechnologies position peaked at $55.2M in Q4 2021.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.